J Clin Neurol.  2018 Jan;14(1):115-117. 10.3988/jcn.2018.14.1.115.

Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer

• Huh SY
• Shin SH
• Kim MK
• Lee SY
• Son KH
• Shin HY

• KMID: 2399612
• DOI: http://doi.org/10.3988/jcn.2018.14.1.115

Abstract

No abstract available.

MeSH Terms

Humans
Myasthenia Gravis*
Myositis*
Thymus Neoplasms*

Reference

1. McDermott J, Jimeno A. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. Drugs Today (Barc). 2015; 51:7–20. PMID: 25685857.

2. Vallet H, Gaillet A, Weiss N, Vanhaecke C, Saheb S, Touitou V, et al. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma. Ann Oncol. 2016; 27:1352–1353. PMID: 26940685.

3. Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016; 60:210–225. PMID: 27084345.

4. Lau KH, Kumar A, Yang IH, Nowak RJ. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve. 2016; 54:157–161. PMID: 27065302.

5. Zhu J, Li Y. Myasthenia gravis exacerbation associated with pembrolizumab. Muscle Nerve. 2016; 54:506–507. PMID: 26802533.

6. Gonzalez NL, Puwanant A, Lu A, Marks SM, Živković SA. Myasthenia triggered by immune checkpoint inhibitors: new case and literature review. Neuromuscul Disord. 2017; 27:266–268. PMID: 28109638.

7. Haddox CL, Shenoy N, Shah KK, Kao JC, Jain S, Halfdanarson TR, et al. Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm. Ann Oncol. 2017; 28:673–675. PMID: 27993808.

8. March KL, Samarin MJ, Sodhi A, Owens RE. Pembrolizumab-induced myasthenia gravis: a fatal case report. J Oncol Pharm Pract. 2017; 1078155216687389. PMID: 28147928.

9. Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017; 82:128–136. PMID: 28666240.